Candriam S.C.A. Summit Therapeutics Inc. Transaction History
Candriam S.C.A.
- $15.6 Billion
- Q1 2025
A detailed history of Candriam S.C.A. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 838,518 shares of SMMT stock, worth $25.2 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
838,518
Previous 842,551
0.48%
Holding current value
$25.2 Million
Previous $15 Million
7.55%
% of portfolio
0.1%
Previous 0.09%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
246Shares Held
87.4MCall Options Held
1.77MPut Options Held
2.48M-
Baker Bros. Advisors LP New York, NY24.4MShares$733 Million5.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$349 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$237 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$197 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$146 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $6.04B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...